News about "Merck"

Merck Doses First Patient in Phase 3 Trial of Investigational ADC for Colorectal Cancer

Merck announces first patient dosing in a phase 3 trial evaluating investigational Antibody Drug Conjugate (ADC) precemtabart tocentecan for metastatic colorectal cancer, targeting CEACAM5 expressed in most colorectal tumors.

Merck | 22/05/2026 | By News Bureau

Merck's Phase 3 TroFuse-005 Trial Shows Survival Benefit of Sac-TMT in Advanced Endometrial Cancer

Merck announced that its phase 3 TroFuse-005 trial evaluating investigational antibody-drug conjugate Sacituzumab Tirumotecan (sac-TMT) met primary endpoints of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.

Merck | 19/05/2026 | By News Bureau

Merck Becomes Sole Testing Provider for FDA-Approved Gene Therapies of Genetix Biotherapeutics

Merck signs a 5-year deal as sole testing provider for Genetix Biotherapeutics’ gene therapies, delivering end-to-end testing to support safe, reliable commercialisation of advanced therapies.

Merck | 08/05/2026 | By News Bureau

Merck Completes USD 5.8 Billion Acquisition of Terns Pharmaceuticals to Strengthen Oncology Pipeline

Merck acquires Terns Pharmaceuticals, advancing development of next-generation therapies for chronic myeloid leukaemia.

Merck | 06/05/2026 | By News Bureau

Merck Wins FDA Approval for Once-Daily IDVYNSO (Doravirine/Islatravir)

IDVYNSO is approved for adults with virologically suppressed HIV-1 with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.

Merck | 23/04/2026 | By News Bureau

Merck Launches Bio-Based Solvents for Sustainable HPLC Applications

Merck introduces bio-based HPLC solvents made from renewable feedstocks, offering lower carbon emissions while maintaining performance for advanced laboratory and analytical applications.

Merck | 22/04/2026 | By News Bureau |  159

Ifinatamab Deruxtecan Gets US Priority Review for Small Cell Lung Cancer

Ifinatamab deruxtecan receives US Priority Review for Small Cell Lung Cancer, supported by Phase 2 data, with potential as a first-in-class B7-H3 targeted Antibody Drug Conjugate.

Merck | 13/04/2026 | By News Bureau |  137

Merck Showcases New Cardio-Pulmonary Data at ACC.26

Merck presented late-breaking data from phase-III and phase-II trials at ACC.26, highlighting advances in its cardio-pulmonary pipeline, including an investigational oral PCSK9 inhibitor and therapies for pulmonary hypertension.

Merck | 17/03/2026 | By News Bureau |  126

Merck reports positive Phase III results for Keytruda and Welireg combination in kidney cancer

Phase III LITESPARK-022 trial shows Keytruda plus Welireg significantly improves disease-free survival in patients with clear cell renal cell carcinoma after surgery, reducing recurrence or death risk by 28 percent.

Merck | 05/03/2026 | By News Bureau |  134

Moderna and Merck Show Durable Five-Year Benefit for Intismeran-KEYTRUDA in Melanoma

At a median five-year follow-up, intismeran autogene plus KEYTRUDA reduced recurrence or death risk by 49 percent versus KEYTRUDA alone, with further data expected and multiple late-stage trials ongoing across tumour types.

Merck | 22/01/2026 | By News Bureau |  121